Drug Profile

NDC 026

Alternative Names: NDC-026

Latest Information Update: 09 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Duchenne muscular dystrophy
New Molecular Entity Yes

18 Sep 2025 Preclinical trials in Duchenne muscular dystrophy in South Korea (unspecified route), prior to September 2025 (DR.NOAH Biotech pipeline, September 2025)
18 Sep 2025 DR.NOAH Biotech received Rare Pediatric Disease Designation (RPDD) for Duchenne muscular dystrophy from the US FDA, prior to September 2025 (DR.NOAH Biotech pipeline, September 2025)
18 Sep 2025 NDC 026 receives Orphan Drug status for Duchenne muscular dystrophy in USA

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com